ERBB2 and neoplasm: The axillary lymph nodes are negative in more than half of these patients, but even among those with clinically node‐positive (cN+) disease, an average of 40 per cent have a pathological complete response (pCR) in the nodes after NAST, with specific subgroups such as human epidermal growth factor receptor 2 (HER2)‐positive tumours showing pCR rates as high as 70 per cent2,.3